CN116239706B - 一种直链茯苓β-葡聚糖及其提取方法和应用 - Google Patents
一种直链茯苓β-葡聚糖及其提取方法和应用 Download PDFInfo
- Publication number
- CN116239706B CN116239706B CN202211326760.2A CN202211326760A CN116239706B CN 116239706 B CN116239706 B CN 116239706B CN 202211326760 A CN202211326760 A CN 202211326760A CN 116239706 B CN116239706 B CN 116239706B
- Authority
- CN
- China
- Prior art keywords
- beta
- poria
- glucan
- linear
- ppca
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 title claims abstract description 36
- 229920002498 Beta-glucan Polymers 0.000 title claims abstract description 36
- 241001619461 Poria <basidiomycete fungus> Species 0.000 title claims abstract description 33
- 238000000605 extraction Methods 0.000 title claims abstract description 21
- 150000004676 glycans Chemical class 0.000 claims abstract description 47
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 46
- 239000005017 polysaccharide Substances 0.000 claims abstract description 46
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000000243 solution Substances 0.000 claims abstract description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 21
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 18
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims abstract description 16
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 16
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000001685 glycyrrhizic acid Substances 0.000 claims abstract description 16
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 16
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 16
- 239000003513 alkali Substances 0.000 claims abstract description 15
- 238000005238 degreasing Methods 0.000 claims abstract description 12
- 229960000583 acetic acid Drugs 0.000 claims abstract description 10
- 239000012362 glacial acetic acid Substances 0.000 claims abstract description 9
- 239000002537 cosmetic Substances 0.000 claims abstract description 8
- 238000004108 freeze drying Methods 0.000 claims abstract description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 25
- 238000002386 leaching Methods 0.000 claims description 21
- 239000000047 product Substances 0.000 claims description 21
- 239000002244 precipitate Substances 0.000 claims description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000012267 brine Substances 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims description 3
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 3
- 239000012498 ultrapure water Substances 0.000 claims description 3
- 241001619444 Wolfiporia cocos Species 0.000 claims 2
- 230000000284 resting effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 1
- 230000002087 whitening effect Effects 0.000 abstract description 4
- 238000003809 water extraction Methods 0.000 abstract description 3
- AVVWPBAENSWJCB-QZABAPFNSA-N beta-D-glucofuranose Chemical group OC[C@@H](O)[C@H]1O[C@@H](O)[C@H](O)[C@H]1O AVVWPBAENSWJCB-QZABAPFNSA-N 0.000 abstract description 2
- 244000248825 Peltandra virginica Species 0.000 abstract 3
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 3
- 229920002307 Dextran Polymers 0.000 abstract 2
- 239000011259 mixed solution Substances 0.000 abstract 1
- 102100028524 Lysosomal protective protein Human genes 0.000 description 33
- 101710162021 Lysosomal protective protein Proteins 0.000 description 33
- 230000000694 effects Effects 0.000 description 23
- 239000000499 gel Substances 0.000 description 16
- 102000003425 Tyrosinase Human genes 0.000 description 15
- 108060008724 Tyrosinase Proteins 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- 244000197580 Poria cocos Species 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 8
- 230000036564 melanin content Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000003020 moisturizing effect Effects 0.000 description 6
- 150000002772 monosaccharides Chemical class 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 206010015946 Eye irritation Diseases 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 231100000013 eye irritation Toxicity 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002356 laser light scattering Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 125000000188 beta-D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 1
- VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- -1 galactosamine hydrochloride monosaccharide Chemical class 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
本发明提供了一种直链茯苓β‑葡聚糖及其提取方法和应用,直链茯苓β‑葡聚糖在DMSO中的分子量为451800g/mol,是β‑D‑呋喃葡萄糖残基以β‑(1→3)‑糖苷键连接而成的直链均一多糖,其提取方法包括如下步骤:将茯苓丁粉碎脱脂,用水提法去除水溶性多糖,再用低温碱提法提取,最后进行脱蛋白纯化,冷冻干燥即得直链茯苓β‑葡聚糖;将提取的直链茯苓β‑葡聚糖溶于碱液,加入甘草酸、冰醋酸混合液制备凝胶产品。本发明提取的茯苓多糖结构简单均一,纯度高,方法简单、成本低,制备的凝胶产品有良好的美白效果,安全可靠,可广泛用于化妆品行业。
Description
技术领域
本发明属于茯苓加工技术领域,具体涉及一种直链茯苓β-葡聚糖及其提取方法和应用。
背景技术
茯苓是多孔菌科茯苓属真菌茯苓Poriacocos(Schw.)Wolf的干燥菌核,作为药物始载于《神农本草经》被列为上品。多糖为茯苓的主要化学成分之一,茯苓多糖约占茯苓菌核总重70~90%,其中水溶性多糖约占3%左右,其余为水不溶性的碱溶性多糖。
关于茯苓多糖提取的报道很多,专利CN110655590A利用水提法+碱液提取获得茯苓多糖,其产品为杂多糖,结构并非简单均一,并且反应过程中反应釜温度高达74-76℃,而碱提法时高温条件会破坏多糖的结构,可能会导致多糖糖苷键断裂。专利CN111349181A利用酶解法提取茯苓多糖,虽然提取条件温和,不易破坏多糖结构,但是对实验要求高,需要寻求合适温度、pH、底物与酶浓度比例等因素,并且提取的多糖同样为杂多糖,结构并非简单均一。
此外,天然多糖凝胶在高分子生物医用材料方面的应用一直被广泛关注,多糖做为一种天然的大分子物质,生物相容性好,以多糖为原料制备的凝胶具有良好的生物相容性,且多糖水凝胶易于降解,制备方法简单。凝胶具有特殊的结构,可以作为基质负载其他具有生物活性的小分子物质,但是以茯苓多糖为原料制备的天然凝胶在化妆品领域的应用并不多。
发明内容
针对现有技术存在的不足,本发明提供了一种直链茯苓β-葡聚糖及其提取方法和应用。
为达到上述目的,本发明采用以下技术方案:
本发明提供一种直链茯苓β-葡聚糖,所述直链茯苓β-葡聚糖在DMSO中的分子量为451800g/mol,是β-D-呋喃葡萄糖残基以β-(1→3)-糖苷键连接而成的直链均一多糖。
本发明还提供上述直链茯苓β-葡聚糖的提取方法,包括以下步骤:
S1、将茯苓丁粉碎过筛,有机溶剂回流脱脂,得脱脂残渣;
S2、取上述脱脂残渣加入盐水浸提过滤,并重复多次,直至滤液中检测不出糖含量,得二次残渣;
S3、取上述二次滤渣加入碱液浸提过滤,并重复1-2次,收集所有滤液;
S4、取S3中滤液用Sevage法脱蛋白过滤,重复多次至无蛋白质沉淀,收集所有上清液,并向上清液中加冰醋酸调pH至中性过滤,收集沉淀并洗涤,洗涤后沉淀经冷冻干燥得茯苓粗多糖;
S5、取上述茯苓粗多糖溶于DMSO溶液中,滴加超纯水并不断搅拌,收集产生的沉淀并冷冻干燥即得直链茯苓β-葡聚糖。
进一步地,所述步骤S1中过筛目数为60-100目,所述有机溶剂为丙酮和乙酸乙酯,分别回流脱脂4-6h,确保脱脂完全。
进一步地,所述步骤S2中盐水为0.9%氯化钠溶液,浸提温度80-100℃,浸提时间3-4h。
进一步地,所述步骤S3中碱液为0.3-0.8mol/L的NaOH水溶液,浸提温度0-5℃,浸提时间1-2h,低浓度碱液和低温浸提保证糖苷键不被破坏,提高提取率。
进一步地,所述步骤S4中所述洗涤依次用按质量体积比1:1加乙醇洗涤,然后再用按质量体积比1:10加水洗涤。
本发明还提供一种直链茯苓β-葡聚糖凝胶产品,利用上述直链茯苓β-葡聚糖来制备,制备方法如下:
(1)将所述直链茯苓β-葡聚糖溶解与碱液中,得多糖溶液;
(2)将甘草酸溶于冰醋酸中形成混合酸,备用;
(3)将(2)中的混合酸加入到(1)中的多糖溶液中调节pH,静置,即得直链茯苓β-葡聚糖凝胶产品。
进一步地,步骤(1)中碱液为0.3-0.8mol/L的NaOH水溶液,多糖溶液中直链茯苓β-葡聚糖浓度为1wt%-3wt%。
进一步地,步骤(3)中甘草酸与多糖溶液的质量体积比为1:1,pH为6-7,静置温度为0~25℃,静置时间1-2h。
上述直链茯苓β-葡聚糖凝胶产品在化妆品中的应用。
与现有技术相比,本发明的有益效果为:
(1)本发明先用水提法去除水溶性多糖,然后通过低温碱提取法提取水不溶性多糖,再去除杂蛋白,最后利用DMSO进行纯化,得到的多糖结构简单均一,提取产率为60±2%、纯度为98.82%;
(2)本发明制备工艺简单,原材料易于取得,绿色环保;
(3)本发明所制备的凝胶产品具有良好的保湿性能、美白活性且能持续释放甘草酸,可以显著降低黑色素含量与酪氨酸酶活性,安全可靠,可广泛适用于化妆品。
附图说明
图1为本发明实施例1中PPCA二维核磁HMBC图;
图2为本发明实施例1中PPCA的SEC-LLS光谱图;
图3为本发明实施例1中PPCA单糖组成图谱;
图4为本发明实施例1中PPCA红外图谱;
图5为本发明实施例3中PPCA-G产品实物图;
图6为本发明实施例3中PPCA-G产品的SEM图;
图7为本发明实施例3中PPCA-GGA产品的缓慢释放曲线图;
图8为本发明实施例3中PPCA-GGA产品对黑色素细胞中黑色素含量影响图;
图9为本发明实施例3中PPCA-GGA产品对黑色素细胞中酪氨酸酶活性影响图。
具体实施方式
下面结合具体实施例对本发明作进一步的详细说明,以使本领域的技术人员更加清楚地理解本发明。
茯苓由湖北辰美中药有限公司提供,生产批号:2121110220;
乙酸乙酯、丙酮、冰醋酸、NaCl、NaOH、DMSO购自国药集团化学试剂有限公司;
磷酸盐缓冲液购自源叶生物科技有限公司;
L-多巴购自上海颖心实验室;
RPMI-1640培养基购自普诺赛生物科技有限公司;
甘草酸标准品购自索莱宝生物科技有限公司;
实验小鼠由辽宁长生生物技术股份有限公司提供,8周龄FVB健康雄性小鼠。
实施例1
实施例提供一种直链茯苓β-葡聚糖的提取方法,具体包括如下步骤:
S1、将茯苓丁粉碎过80目筛,用150目纱布样品袋装载后放入索氏提取器,使用丙酮和乙酸乙酯分别回流6h,收集脱脂残渣。
S2、取上述脱脂残渣加入0.9%氯化钠溶液,加热到90℃搅拌4h,收集滤渣,并重复多次,采用苯酚硫酸法检测,直至滤液中检测不出糖含量,收集二次残渣。
S3、取上述二次滤渣加入0.5mol/LNaOH水溶液,在5℃条件下搅拌2h,收集滤液,并重复2次,收集所有滤液。
S4、取S3中滤液,按照滤液:氯仿:正丁醇=25:5:1,采用Sevage法脱蛋白,搅拌30min,并重复3次过滤,收集所有上清液,向上清液中加99%冰醋酸调pH至中性并不断搅拌,直至产生大量沉淀,收集沉淀,并将沉淀按照质量体积比1:1加入95%乙醇,混合均匀后静置6h,收集沉淀,再取醇洗后的沉淀,按照质量体积比1:10加入蒸馏水,搅拌均匀后收集沉淀,并重复3次后收集所得沉淀即为茯苓粗多糖。
S5、取上述茯苓粗多糖溶于DMSO中,得浓度为1mg/mL的茯苓粗多糖DMSO溶液,使用恒压滴液漏斗逐滴滴加超纯水并不断搅拌,收集产生的沉淀并冷冻干燥即得直链茯苓β-葡聚糖,并命名为PPCA。
将所得PPCA的结构进行鉴定,包括以下步骤:
1)分子量:对实施例1获得的PPCA采用尺寸排除色谱-激光光散射仪联用装置进行纯度和分子量鉴定。
色谱柱:采用凝胶排阻色谱柱(OhpakSB-805HQ(300×8mm),OhpakSB-804HQ(300×8mm)和OhpakSB-803HQ(300×8mm)串联。柱温60℃;进样量100μL;流动相B(0.5%LiBr,DMSO),流速0.3ml/min,检测器:示差检测器为OptilabT-rEX(Wyatttechnology,CA,USA),激光光散射检测器为DAWNHELEOSⅡ(Wyatttechnology,CA,USA)。
表1PPCA的分子量
如图2所示:其分子量分布呈现唯一、较窄对称峰,表明PPCA的分子量分布较窄,是一种均一多糖,在DMSO中的分子量为451800g/moL。
2)单糖组成分析:
采用离子色谱对PPCA的单糖组成进行分析,取干净的色谱瓶,精确称量多糖样品5mg(±0.05mg),加入1ml2MTFA酸溶液,121℃加热2小时。通氮气,吹干。加入3mL甲醇清洗,再吹干,重复甲醇清洗2-3次。加入5mL无菌水溶解,转入色谱瓶中待测。采用ThermoU3000液相色谱系统。
标准品溶液的配制:依次称取鼠李糖、阿拉伯糖、半乳糖、葡萄糖、木糖、甘露糖、半乳糖醛酸、葡萄糖醛酸、氨基葡萄糖盐酸盐、氨基半乳糖盐酸盐单糖各5mg,岩藻糖10mg,溶解后用容量瓶定容至10ml,配制成标准品母液。按照下表2的标准品序列配置混标,进行离子色谱分析。色谱柱为ZORBAXEclipseXDB-C18,流动相为乙腈:磷酸盐缓冲液(磷酸二氢钾12g/L,2MNaOH调整PH至pH=6.8)等度洗脱,乙腈和磷酸盐缓冲液的体积比为17:83,流速为0.8ml/min,柱温30℃,检测波长250nm,进样量10μl。
表2混标中单糖标准品浓度及出峰时间
如图3所示:PPCA单糖由葡萄糖组成。
3)键接方式测试分析:
采用FT-IR分析PPCA结构,结果如图4,吸收带在3600~3200cm-1是-OH的伸缩震动吸收峰,为糖类的特征峰。在891cm-1处有吸收峰,表明PPCA为β构型的葡聚糖。
经一维和二维核磁共振分析(如下表3所示),13C核磁共振谱图只有六个特征碳的吸收峰,并没有其他杂峰。其中,只在δ103.51ppm处显示了一个异头碳(C-1)信号峰峰,表明它只存在唯一一种糖残基,通常β-异头碳连接的多糖C-1峰高于100ppm,而α-异头碳连接的多糖C-1峰低于100ppm,表明为PPCA为β多糖并且纯度较高,不含α多糖杂质。在低场范围(160-200ppm区域)未出现位移峰,表明不存在羰基峰,进一步证明PPCA为中性多糖,这与前文中FT-IR及元素分析结果相吻合。与13CNMR谱相比,由于存在H-H间相互耦合裂分峰,多糖1HNMR谱图往往比较复杂难以解析。HMBC谱图反映与C原子直接相连的H原子与C原子间的耦合信息,在谱图中以交叉的点表现出来。若C的信号峰已经进行了归属,就可解析出1H谱,归属结果列在表3中。再从它的13C-1H HMBC碳氢相关二维核磁共振谱图中的化学位移值和近似的耦合常数,可以断定它是一种重复单元为葡萄糖的线型β-(1→3)-D-葡聚糖。可知PPCA是β-D-葡萄糖残基以β-(1→3)-糖苷键连接而成的直链均一多糖。
表3PPCA的氢谱和碳谱化学位移归属
NMR实验步骤:称取多糖样品50mg,将其溶于0.5ml的DMSO-d6中并冷冻干燥。随后将冻干粉再溶于0.5ml的重水中,并继续冷冻干燥,重复以上过程,以充分交换活泼氢。然后将样品溶于0.5ml的重水中,在室温25℃下置于以600MHz的核磁共振仪测定1HNMR谱、13CNMR谱和二维图谱。
PPCA的1H和13C的化学位移归属如上表3所示。结合单糖组成的结果可知PPCA是一种直链的β-葡聚糖。
最终确定:PPCA分子量为451800g/moL,是β-D-葡萄糖残基以β-(1→3)-糖苷键连接的直链β-葡聚糖。
PPCA对酪氨酸酶活性的影响:
将新鲜马铃薯-20℃预冷10h,去皮,切成碎块,取10g预冷的马铃薯置于研钵中,按(m/v=1:1)加入磷酸盐缓冲液(PH=6.86),捣碎,顺时针研磨1min(冰上),4000rpm离心10min,分离出上清置于冰上,3h内用尽。精密称定PPCA冻干品,溶于DMSO,配制成浓度为0.2mg/mL的多糖溶液。精密称定L-Dopa(L-多巴),溶于PH=6.86的磷酸盐缓冲液(PBS)中,使终浓度为1mg/mL。将各测试样混匀,将每个样品中的1~4种测试样混匀,将样品与酶混匀37℃,水浴10min,加入1ml底物反应10min,立即以475nm处测吸光度。按下式计算提取物对酪氨酸酶的抑制率。
表4PPCA对酪氨酸酶活性测定
其中测试样1结果为A1,测试样2结果为A2,测试样3结果为A3,测试样4结果为A4。
最终结果得出PPCA对酪氨酸酶活性抑制率为40.5%。
对比例1:
本对比例提供一种直链茯苓β-葡聚糖提取方法,其采用的原料及工艺步骤与实施例1的基本相同,区别在于:在步骤S4中,碱液提取温度换成25℃,其余条件不变。并将其制备的PPCA进行酪氨酸酶活性的影响实验,实验方法和实施例1中方法完全相同,实验结果见表5。
对比例2:
本对比例提供一种直链茯苓β-葡聚糖提取方法,其采用的原料及工艺步骤与实施例1的基本相同,区别在于:在步骤S4中,碱提多糖不使用sevage法脱蛋白,其余条件不变。并将其制备的PPCA进行酪氨酸酶活性的影响实验,实验方法和实施例1中方法完全相同,实验结果见表5。
表5实施例1和对比例1、2PPCA对酪氨酸酶抑制率结果
由表5结果可知,当碱液提取温度换成25℃或多糖不使用sevage法脱蛋白其制备的PPCA对酪氨酸酶抑制率较差,原因可能是25℃条件下碱液提取可能破坏了PPCA之间糖苷键,导致其活性下降;且未经脱蛋白时里面的杂蛋白也会影响PPCA活性。
实施例2
(1)将实施例1制备的PPCA溶解溶解于0.5mol/L的NaOH中配置成浓度为20mg/mL的多糖溶液。
(2)将甘草酸溶于99%冰醋酸中形成混合酸,备用。
(3)按照甘草酸与多糖溶液的质量体积比为1:1,将(2)中的混合酸加入到(1)中的多糖溶液中调节pH至7,4℃静置1h,即得直链茯苓β-葡聚糖凝胶产品,命名为PPCA-GGA。
将上述制备的PPCA-GGA进行保湿效果实验,具体实验步骤如下:
将所制备的PPCA-GGA称重,记为m0。然后将凝胶置于相对湿度为30%±5%的环境中,分别于0.5h、1.0h、1.5h、2.0h、4.0、6.0h、8.0h、10.0h、12.0h时称重,记为mi,上述实验重复3次,保湿率=(mi/m0)*100%
表6PPCA-GGA保湿率
结果表明,PPCA-GGA具有良好的保湿效果,在0.5h时保湿率高达95.54±0.06%。
将上述制备的PPCA-GGA进行长效释放效果实验,具体实验步骤如下:
将PPCA-GGA分别置于20ml pH分别为5.0、6.8、7.4的磷酸盐缓冲液PBS中,将该体系置于37℃,rpm为80的孵育箱中振摇,分别于1、2、4、6、8、10、12h取4ml浸提液,并补充添加等量的磷酸盐缓冲液。
采用HPLC对浸提液中的甘草酸含量进行检测。色谱柱为:AgilentZORBAXSB-C18(4.6×250nm);流动相为2%醋酸:甲醇=27:73;检测波长为237nm;柱温:30℃;流速:1ml/min;进样量10μL。
长效释放效果结果见图7,结果表明:PPCA-GGA在12h内能够缓慢的释放甘草酸,在不同的PH环境下释放率有所不同。且随着浸提时间的增长,释放率在不断增加。在pH=5.0的缓冲介质中,甘草酸8h时释放率为20.18±2.08%;在pH=6.8的缓冲介质中,甘草酸8h时释放率为26.22±0.98%;在PH=7.4的缓冲介质中,甘草酸8h时释放率为18.99±2.25%。
实施例3
PPCA-GGA在美白效果中的应用,本实施例所述PPCA-GGA均为实施例2制备的PPCA-GGA。
利用PPCA-GGA对小鼠黑色素瘤细胞中黑色素含量、氨酸酶活性以及对小鼠皮肤刺激、眼刺激这四组实验来进行表征。
1.PPCA-GGA对小鼠黑色素瘤细胞中黑色素含量具体步骤如下:
制备空白凝胶:和实施例2制备的PPCA-GGA采用的原料及工艺步骤基本相同,区别在于:制备过程中不使用甘草酸,仅用冰醋酸调节pH至7,4℃静置1h,即得空白凝胶产品,命名为PPCA-G。
使用培养基分别浸提空白凝胶和PPCA-GGA 10h,得凝胶浸提培养基。然后将处于对数生长期的B16细胞接种于55cm×16cm的培养皿,并随机分为空白对照组、PPCA-G组、PPCA-GGA组,培养24h后,弃去上清,按照分组依次加入空白培养基、PPCA-G浸提培养基、PPCA-GGA浸提培养基,培养24h。采用NaOH裂解法,使用1mol/LNaOH裂解细胞,100℃水浴30min,离心,取上清,将上清加入96孔板,于450nm处测定吸光度,黑色素含量=(OD实验×106)/n×100%。
表7各组黑色素细胞黑色素含量
如图8、表7所示,结果表明:与空白对照组相比,PPCA-G组和PPCA-GGA组黑色素瘤细胞中黑色素含量显著降低,且PPCA-GGA组效果比PPCA-G组更明显。
2.PPCA-GGA对小鼠黑色素瘤细胞中酪氨酸酶活性影响具体步骤如下:
采用多巴氧化法,首先提前配制好1%TritonX-100溶液和0.1%L-DOPA溶液备用。
将处于对数生长期的细胞接种于96孔板中,将细胞随机分为对照组、PPCA-G组、PPCA-GGA组,培养24h。按照分组依次加入空白培养基、PPCA-G浸提培养基、PPCA-GGA浸提培养基后继续培养24h,将96孔板上清液弃去,每孔依次加入100μLTritonX-100溶液,在-80℃温度下冻存1h,而后室温下使其融化裂解,每孔依次加0.1%L-DOPA100μL,于37℃培养箱孵育2h,置酶标仪下测定其在490nm处OD值。
酪氨酸酶活性=(OD实验-OD空白)/(OD正常-OD空白)×100%。
表8各组黑色素细胞酪氨酸酶活性
如图9、表8所示,结果表明,与空白组相比,PPCA-G组和PPCA-GGA组黑色素瘤细胞中酪氨酸酶活性显著降低,且PPCA-GGA组效果比PPCA-G组更明显。
3.PPCA-GGA对小鼠皮肤刺激性试验具体步骤如下:
随机选取4只雄性小鼠,试验开始前24h将动物背部脊柱两侧毛剃掉,去毛范围左右各约3cm×3cm。取PPCA-GGA0.5g,涂抹于一侧去毛皮肤处,另一侧作为空白对照。采用封闭实验,敷用24h后用温水洗去残留物,去除受试物后,分别于1、24、48h观察涂抹部位的皮肤反应,按《化妆品安全技术规范》评分标准进行皮肤反应积分和刺激强度评价(皮肤刺激强度评价标准:0~0.4无刺激性;0.5~2.9轻刺激性;3.0~5.9中等刺激性;6.0~8.0强刺激性),以受试动物积分的平均值进行综合评价,根据24h、48h和72h各观察时点最高积分均值。
表9 PPCA-GGA对小鼠皮肤刺激性实验结果
试验结果表明,PPCA-GGA对小鼠皮肤刺激性等级为无刺激。
4.PPCA-GGA对小鼠眼刺激性试验具体步骤如下:
随机选取4只雄性小鼠,取PPCA-GGA0.1g滴入试验动物一侧的结膜囊内,另一侧作为对照。滴药后使眼被动闭合5~10s,防止受试物流出,另一侧眼睛不做处理,作为对照,滴入受试物后24h内不冲洗眼睛,在滴入受试物后1h、24h、48h、72h以及第4d和第7d对动物眼睛进行检查,如果72h未出现刺激反应,即可终止试验。按《化妆品安全技术规范》进行眼刺激性评价和眼刺激性强度判定(眼刺激强度评价标准:0~0.4无刺激性;0.5~2.9轻刺激性;3.0~5.9中等刺激性;6.0~8.0强刺激性)。
表10PPCA-GGA对小鼠眼刺激实验结果
试验结果表明,PPCA-GGA对小鼠眼刺激性等级为无刺激。
通过以上多项结果说明,本发明提供直链茯苓β-葡聚糖结构简单均一,所制备的凝胶产品具有良好的保湿性能、美白活性且能持续释放甘草酸,将其制备成PPCA-GGA可以更显著降低黑色素含量与酪氨酸酶活性,广泛适用于化妆品。
本发明中未对具体描述试剂、设备等均为现有技术中已经成熟运营,可以从市面上直接购买得到。
以上仅为本发明的较佳实施方案,并非用于限定本发明的保护范围。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (4)
1.一种直链茯苓β-葡聚糖凝胶产品,其特征在于,利用直链茯苓β-葡聚糖来制备,制备方法如下:
(1)将所述直链茯苓β-葡聚糖溶解与碱液中,得多糖溶液;
(2)将甘草酸溶于冰醋酸中形成混合酸,备用;
(3)将(2)中的混合酸加入到(1)中的多糖溶液中,调节pH,静置,即得直链茯苓β-葡聚糖凝胶产品;
所述的直链茯苓β-葡聚糖的提取方法,包括以下步骤:
S1、将茯苓丁粉碎过筛,有机溶剂回流脱脂,得脱脂残渣;
S2、取上述脱脂残渣加入盐水浸提过滤,并重复多次,直至滤液中检测不出糖含量,得二次残渣;
S3、取上述二次滤渣加入碱液浸提过滤,并重复1-2次,收集所有滤液;
S4、取S3中滤液用Sevage法脱蛋白过滤,收集所有上清液,并向上清液中加冰醋酸调pH至中性过滤,收集沉淀并洗涤,洗涤后的沉淀经冷冻干燥,得茯苓粗多糖;
S5、取上述茯苓粗多糖溶于DMSO溶液中,滴加超纯水并不断搅拌,收集产生的沉淀并冷冻干燥,即得直链茯苓β-葡聚糖;
所述步骤S1中过筛目数为60-100目,所述有机溶剂为丙酮和乙酸乙酯,分别回流脱脂4-6h;
所述步骤S2中盐水为0.9%氯化钠溶液,浸提温度80-100℃,浸提时间3-4h;
所述步骤S3中碱液为0.3-0.8mol/L的NaOH,浸提温度0-5℃,浸提时间1-2h;
所述步骤S4中所述洗涤依次用按质量体积比1:1加乙醇洗涤,然后再用按质量体积比1:10加水洗涤。
2.根据权利要求1所述的直链茯苓β-葡聚糖凝胶产品,其特征在于,步骤(1)中碱液为0.3-0.8mol/L的NaOH水溶液,多糖溶液中直链茯苓β-葡聚糖浓度为1wt%-3wt%。
3.根据权利要求2所述的直链茯苓β-葡聚糖凝胶产品,其特征在于,步骤(3)中甘草酸与多糖溶液的质量体积比为1:1,pH为6-7,静置温度为0-25℃,静置时间1-2h。
4.权利要求1至3任一项所述的直链茯苓β-葡聚糖凝胶产品在制备化妆品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211326760.2A CN116239706B (zh) | 2022-10-24 | 2022-10-24 | 一种直链茯苓β-葡聚糖及其提取方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211326760.2A CN116239706B (zh) | 2022-10-24 | 2022-10-24 | 一种直链茯苓β-葡聚糖及其提取方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116239706A CN116239706A (zh) | 2023-06-09 |
CN116239706B true CN116239706B (zh) | 2024-06-21 |
Family
ID=86623061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211326760.2A Active CN116239706B (zh) | 2022-10-24 | 2022-10-24 | 一种直链茯苓β-葡聚糖及其提取方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116239706B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102603916A (zh) * | 2012-03-21 | 2012-07-25 | 丁友玲 | (1-3)-β-D-葡聚糖的精制方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201020191D0 (en) * | 2010-11-29 | 2011-01-12 | Biotec Pharmacon Asa | Glucan gels |
CN104628861A (zh) * | 2015-02-03 | 2015-05-20 | 丹娜(天津)生物科技有限公司 | 一种1,3-β-D-葡聚糖多克隆抗体及其制备方法 |
CN106366211A (zh) * | 2016-08-23 | 2017-02-01 | 张巧玉 | 一种茯苓多糖的制备工艺及其应用 |
CN109593142B (zh) * | 2018-12-21 | 2020-06-26 | 江南大学 | 一种减少β-1,3葡聚糖在干燥过程中凝胶强度损失的方法 |
CN112778436A (zh) * | 2019-11-08 | 2021-05-11 | 天津一瑞生物科技股份有限公司 | 茯苓中提取β-1,3-D-葡聚糖的方法 |
CN116546890A (zh) * | 2020-11-17 | 2023-08-04 | 西姆莱斯股份公司 | 包含谷物β-葡聚糖或含β-葡聚糖的谷物提取物的液体组合物 |
CN113717294A (zh) * | 2021-08-20 | 2021-11-30 | 湖北中医药大学 | 一种菊粉型党参果聚糖cpw1及其制备方法与应用 |
-
2022
- 2022-10-24 CN CN202211326760.2A patent/CN116239706B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102603916A (zh) * | 2012-03-21 | 2012-07-25 | 丁友玲 | (1-3)-β-D-葡聚糖的精制方法 |
Non-Patent Citations (1)
Title |
---|
茯苓中碱溶性多糖的提取及其超微粉碎改性研究;梅光明;李孚杰;沈思;黄文;;食品科学;20071015(10);278-283 * |
Also Published As
Publication number | Publication date |
---|---|
CN116239706A (zh) | 2023-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022016644A1 (zh) | 一种刺五加均一多糖及其制备方法及应用 | |
CN111533820A (zh) | 一种三七多糖及其制备方法与应用 | |
CN110183542B (zh) | 一种杨树桑黄多糖的提取方法 | |
CN108503723A (zh) | 用于制备多聚甘露糖提取物细粉的方法及组合物 | |
AU2018202402B2 (en) | Homogeneous polysaccharide with immunoregulation activity and preparation method thereof | |
CN116239706B (zh) | 一种直链茯苓β-葡聚糖及其提取方法和应用 | |
CN113121718A (zh) | 一种迷果芹多糖psgp-2及其制备方法与应用 | |
CN115166089A (zh) | 一种利用甲基化硫酸寡糖组鉴别蛋白核小球藻的方法 | |
CN112794928B (zh) | 一种黑枣多糖及其应用 | |
CN113880963A (zh) | 一种桑黄多糖及其制备方法和应用 | |
CN115232220A (zh) | 一种灵芝多糖及其提取方法和应用 | |
US11369627B2 (en) | Myrtle polysaccharide P1, the separation method thereof and the use in preparing hypolipidemic drugs therefor | |
CN111040042B (zh) | 一种枸杞多糖、制备方法及其应用 | |
CN113244258A (zh) | 一种螺旋藻多糖促炎症酶诱导剂的制备方法及应用 | |
CN112778430A (zh) | 一种硫酸化修饰青钱柳多糖及其制备方法和应用 | |
CN117964790B (zh) | 盐地碱蓬多糖及其制备方法和应用 | |
CN110894244B (zh) | 一种土鳖虫多糖的结构及其用途 | |
CN116655822B (zh) | 葡聚糖及其制备方法、抗氧化试剂、免疫调节试剂和应用 | |
CN110511292B (zh) | 冬虫夏草提取物与用途 | |
US20240156855A1 (en) | Method for extracting lactarius hatsudake tanaka polysaccharide compound | |
CN112759661B (zh) | 金樱子多糖制备方法、鉴定方法和应用 | |
CN116425901B (zh) | 苦笋多糖及其制备方法和用途 | |
CN116120475B (zh) | 一种云莓均一多糖rcp-90-1及其分离纯化方法和作为抗肿瘤药物的应用 | |
CN111748045B (zh) | 亨氏马尾藻岩藻聚糖硫酸酯制备方法及应用 | |
US20230293574A1 (en) | Fish swim bladder-derived heparin-like mucopolysaccharide and methods of making and using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |